Citations (64)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Claudia Penafuerte, Matthew Feldhammer, John R. Mills, Valerie Vinette, Kelly A. Pike, Anita Hall, Eva Migon, Gerard Karsenty, Jerry Pelletier, George Zogopoulos & Michel L. Tremblay. (2017) Downregulation of PTP1B and TC-PTP phosphatases potentiate dendritic cell-based immunotherapy through IL-12/IFNγ signaling. OncoImmunology 6:6.
Read now
Read now
Theresa L Whiteside. (2015) The role of regulatory T cells in cancer immunology. ImmunoTargets and Therapy 4, pages 159-171.
Read now
Read now
Alison Sehgal, Theresa L Whiteside & Michael Boyiadzis. (2015) Programmed death-1 checkpoint blockade in acute myeloid leukemia. Expert Opinion on Biological Therapy 15:8, pages 1191-1203.
Read now
Read now
Michael D Oberst, Stacy Fuhrmann, Kathy Mulgrew, Maria Amann, Lily Cheng, Petra Lutterbuese, Laura Richman, Steve Coats, Patrick A Baeuerle & Scott A Hammond. (2014) CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas. mAbs 6:6, pages 1571-1584.
Read now
Read now
Theresa L Whiteside. (2014) Induced regulatory T cells in inhibitory microenvironments created by cancer. Expert Opinion on Biological Therapy 14:10, pages 1411-1425.
Read now
Read now
Sylvia Muller-Haegele, Laurent Muller & Theresa L Whiteside. (2014) Immunoregulatory activity of adenosine and its role in human cancer progression. Expert Review of Clinical Immunology 10:7, pages 897-914.
Read now
Read now
Constantin N Baxevanis, Michael Papamichail & Sonia A Perez. (2014) Therapeutic cancer vaccines: a long and winding road to success. Expert Review of Vaccines 13:1, pages 131-144.
Read now
Read now
Magis Mandapathil & Theresa L Whiteside. (2011) Targeting human inducible regulatory T cells (Tr1) in patients with cancer: blocking of adenosine–prostaglandin E2 cooperation. Expert Opinion on Biological Therapy 11:9, pages 1203-1214.
Read now
Read now
Articles from other publishers (56)
V. L. Rybkina, G. V. Adamova & D. S. Oslina. (2023) The role of cytokines in the pathogenesis of malignant neoplasms. Сибирский научный медицинский журнал 43:2, pages 15-28.
Crossref
Crossref
Binhan Wang, Manni Wang, Danyi Ao & Xiawei Wei. (2022) CXCL13-CXCR5 axis: Regulation in inflammatory diseases and cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1877:5, pages 188799.
Crossref
Crossref
Roni Touboul & Benjamin Bonavida. 2021. YY1 in the Control of the Pathogenesis and Drug Resistance of Cancer. YY1 in the Control of the Pathogenesis and Drug Resistance of Cancer
289
309
.
Muzammal Hussain, Dickson Adah, Muqddas Tariq, Yongzhi Lu, Jiancun Zhang & Jinsong Liu. (2019) CXCL13/CXCR5 signaling axis in cancer. Life Sciences 227, pages 175-186.
Crossref
Crossref
Jadwiga Jablonska, Monika Pietrowska, Sonja Ludwig, Stephan Lang & Basant Kumar Thakur. (2019) Challenges in the Isolation and Proteomic Analysis of Cancer Exosomes—Implications for Translational Research. Proteomes 7:2, pages 22.
Crossref
Crossref
Demétrius Eduardo Germini, Maria Isete Fares Franco, Fernando Luiz Affonso Fonseca, Flávia de Sousa Gehrke, Beatriz da Costa Aguiar Alves Reis, Leonardo Cardili, Celina Tizuko Fujiyama Oshima, Thérèse Rachell Theodoro & Jaques Waisberg. (2019) Association of expression of inflammatory response genes and DNA repair genes in colorectal carcinoma. Tumor Biology 41:4, pages 101042831984304.
Crossref
Crossref
Laura Ridolfi, Francesco de Rosa, Laura Fiammenghi, Massimiliano Petrini, Anna Maria Granato, Valentina Ancarani, Elena Pancisi, Valentina Soldati, Serena Cassan, Jenny Bulgarelli, Angela Riccobon, Giorgia Gentili, Oriana Nanni, Massimo Framarini, Francesca Tauceri & Massimo Guidoboni. (2018) Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial). BMJ Open 8:8, pages e021701.
Crossref
Crossref
Sifeng Qu, Hui Xue, Xin Dong, Dong Lin, Rebecca Wu, Noushin Nabavi, Colin C. Collins, Martin E. Gleave, Peter W. Gout & Yuzhuo Wang. (2018) Aneustat (OMN54) has aerobic glycolysis-inhibitory activity and also immunomodulatory activity as indicated by a first-generation PDX prostate cancer model. International Journal of Cancer 143:2, pages 419-429.
Crossref
Crossref
Friedemann Schad, Anja Thronicke, Antje Merkle, Harald Matthes & Megan L. Steele. (2017) Immune-related and adverse drug reactions to low versus high initial doses of Viscum album L. in cancer patients. Phytomedicine 36, pages 54-58.
Crossref
Crossref
Chengkuan Cai, Jingyuan Tang, Baixin Shen, Liucheng Ding, Yunpeng Shao, Zhengsen Chen, Yinchao Ma, Haoliang Xue & Zhongqing Wei. (2017) Preclinical trial of the multi-targeted lenvatinib in combination with cellular immunotherapy for treatment of renal cell carcinoma. Experimental and Therapeutic Medicine 14:4, pages 3221-3228.
Crossref
Crossref
Andrea Maglioco, Damián G. Machuca, María Noel Badano, Paula Nannini, Gabriela V. Camerano, Héctor Costa, Roberto Meiss, Raúl A. Ruggiero, Mirta Giordano & Graciela I. Dran. (2017) B cells inhibit the antitumor immunity against an established murine fibrosarcoma. Oncology Letters 13:5, pages 3225-3232.
Crossref
Crossref
Jia Li, Chang-Lin Zou, Zhi-Ming Zhang, Lian-Jie Lv, Hai-Bo Qiao & Xiu-Ju Chen. (2017) A multi-targeted tyrosine kinase inhibitor lenvatinib for the treatment of mice with advanced glioblastoma. Molecular Medicine Reports 16:5, pages 7105-7111.
Crossref
Crossref
Kai Li, Shuai Qu, Xi Chen, Qiong Wu & Ming Shi. (2017) Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways. International Journal of Molecular Sciences 18:2, pages 404.
Crossref
Crossref
Giselle Hevia, Isabel Pablos, Marilyn Clavell, Judith Raymond, Mayrel Labrada & Luis E. Fernández. (2017) Cyclooxygenase Inhibition in Cancer Immunotherapy: Combination of Indomethacin with Cancer Vaccines Is Not Always Beneficial. Journal of Cancer Therapy 08:02, pages 188-209.
Crossref
Crossref
Audry Fernández, Amaury Pupo, Karel Mena-Ulecia & Carlos Gonzalez. (2016) Pharmacological Modulation of Proton Channel Hv1 in Cancer Therapy: Future Perspectives. Molecular Pharmacology 90:3, pages 385-402.
Crossref
Crossref
Dickson Adah, Muzammal Hussain, Limei Qin, Li Qin, Jiancun Zhang & Xiaoping Chen. (2016) Implications of MDSCs-targeting in lung cancer chemo-immunotherapeutics. Pharmacological Research 110, pages 25-34.
Crossref
Crossref
Theresa L. Whiteside. 2016. Manual of Molecular and Clinical Laboratory Immunology. Manual of Molecular and Clinical Laboratory Immunology
1036
1050
.
M. Mandapathil. (2016) Adenosine-mediated immunosuppression in patients with squamous cell carcinoma of the head and neckAdenosinvermittelte Immunsuppression bei Patienten mit Kopf-Hals-Plattenepithelkarzinomen. HNO 64:5, pages 303-309.
Crossref
Crossref
Olivera J Finn & Pamela L Beatty. (2016) Cancer immunoprevention. Current Opinion in Immunology 39, pages 52-58.
Crossref
Crossref
Muzammal Hussain, Zahir Shah, Nasir Abbas, Aqeel Javeed, Muhammad Mahmood Mukhtar & Jiancun Zhang. (2016) Targeting tumor-associated immune suppression with selective protein kinase A type I (PKAI) inhibitors may enhance cancer immunotherapy. Medical Hypotheses 86, pages 56-59.
Crossref
Crossref
Jaina M. Patel, Vincent F. Vartabedian, Erica N. Bozeman, Brianne E. Caoyonan, Sanjay Srivatsan, Christopher D. Pack, Paulami Dey, Martin J. D'Souza, Lily Yang & Periasamy Selvaraj. (2016) Plasma membrane vesicles decorated with glycolipid-anchored antigens and adjuvants via protein transfer as an antigen delivery platform for inhibition of tumor growth. Biomaterials 74, pages 231-244.
Crossref
Crossref
Muzammal Hussain, Fei Tang, Jinsong Liu, Jiancun Zhang & Aqeel Javeed. (2015) Dichotomous role of protein kinase A type I (PKAI) in the tumor microenvironment: A potential target for ‘two-in-one’ cancer chemoimmunotherapeutics. Cancer Letters 369:1, pages 9-19.
Crossref
Crossref
Theresa L. Whiteside. (2014) Clinical Impact of Regulatory T cells (Treg) in Cancer and HIV. Cancer Microenvironment 8:3, pages 201-207.
Crossref
Crossref
Ross Stewart, Michelle Morrow, Scott A. Hammond, Kathy Mulgrew, Danielle Marcus, Edmund Poon, Amanda Watkins, Stefanie Mullins, Matthieu Chodorge, John Andrews, David Bannister, Emily Dick, Nicola Crawford, Julie Parmentier, Marat Alimzhanov, John S. Babcook, Ian N. Foltz, Andrew Buchanan, Vahe Bedian, Robert W. Wilkinson & Matthew McCourt. (2015) Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody. Cancer Immunology Research 3:9, pages 1052-1062.
Crossref
Crossref
Dewan M. S. Hossain, Sumanta K. Pal, Dayson Moreira, Priyanka Duttagupta, Qifang Zhang, Haejung Won, Jeremy Jones, Massimo D'Apuzzo, Stephen Forman & Marcin Kortylewski. (2015) TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients. Clinical Cancer Research 21:16, pages 3771-3782.
Crossref
Crossref
Jacob L. Goldberg & Paul M. Sondel. (2015) Enhancing Cancer Immunotherapy Via Activation of Innate Immunity. Seminars in Oncology 42:4, pages 562-572.
Crossref
Crossref
Rohit Mittal, Ching-Wen Chen, John D. Lyons, Lindsay M. Margoles, Zhe Liang, Craig M. Coopersmith & Mandy L. Ford. (2015) Murine lung cancer induces generalized T-cell exhaustion. Journal of Surgical Research 195:2, pages 541-549.
Crossref
Crossref
Xu Qian, Andreas M. Kaufmann & Andreas E. Albers. 2015. Cancer Immunology. Cancer Immunology
299
311
.
Sébastien Anguille, Evelien L Smits, Eva Lion, Viggo F van Tendeloo & Zwi N Berneman. (2014) Clinical use of dendritic cells for cancer therapy. The Lancet Oncology 15:7, pages e257-e267.
Crossref
Crossref
Takeo Hasegawa, Hiroyuki Suzuki, Takumi Yamaura, Satoshi Muto, Naoyuki Okabe, Jun Osugi, Mika Hoshino, Mitsunori Higuchi, Kazuya Ise & Mitsukazu Gotoh. (2014) Prognostic value of peripheral and local forkhead box p3+ regulatory T�cells in patients with non-small‑cell lung cancer. Molecular and Clinical Oncology.
Crossref
Crossref
Kevin H. Toomer & Zhibin Chen. (2014) Autoimmunity as a Double Agent in Tumor Killing and Cancer Promotion. Frontiers in Immunology 5.
Crossref
Crossref
Ahmad A. Tarhini, Howard Edington, Lisa H. Butterfield, Yan Lin, Yongli Shuai, Hussein Tawbi, Cindy Sander, Yan Yin, Matthew Holtzman, Jonas Johnson, Uma N. M. Rao & John M. Kirkwood. (2014) Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab. PLoS ONE 9:2, pages e87705.
Crossref
Crossref
Theresa L. Whiteside. 2014. Advances in Tumor Immunology and Immunotherapy. Advances in Tumor Immunology and Immunotherapy
343
363
.
Bertrand Allard, Sandra Pommey, Mark J. Smyth & John Stagg. (2013) Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs. Clinical Cancer Research 19:20, pages 5626-5635.
Crossref
Crossref
Manuela Schmidinger. (2013) Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors. European Journal of Cancer Supplements 11:2, pages 172-191.
Crossref
Crossref
Maria Jure-Kunkel, Gregg Masters, Emel Girit, Gennaro Dito, Francis Lee, John T. Hunt & Rachel Humphrey. (2013) Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models. Cancer Immunology, Immunotherapy 62:9, pages 1533-1545.
Crossref
Crossref
Muzammal Hussain, Aqeel Javeed, Muhammad Ashraf, Hou Yuzhu & Muhammad Mahmood Mukhtar. (2013) Multilevel pharmacological manipulation of adenosine–prostaglandin E2/cAMP nexus in the tumor microenvironment: A ‘two hit’ therapeutic opportunity. Pharmacological Research 73, pages 8-19.
Crossref
Crossref
Bodo E Lippitz. (2013) Cytokine patterns in patients with cancer: a systematic review. The Lancet Oncology 14:6, pages e218-e228.
Crossref
Crossref
Victoria L. Green, Anna Michno, Nicholas D. Stafford & John Greenman. (2013) Increased prevalence of tumour infiltrating immune cells in oropharyngeal tumours in comparison to other subsites: relationship to peripheral immunity. Cancer Immunology, Immunotherapy 62:5, pages 863-873.
Crossref
Crossref
Theresa L WhitesideTheresa L Whiteside. 2013. Personalized Management of Head & Neck Cancer. Personalized Management of Head & Neck Cancer
2
8
.
Theresa L Whiteside. 2013. Personalized Management of Head & Neck Cancer. Personalized Management of Head & Neck Cancer.
Tomoyuki Tano, Masato Okamoto, Shin Kan, Koh-ichi Nakashiro, Shigetaka Shimodaira, Shigeo Koido, Sadamu Homma, Mitsunobu Sato, Tomonobu Fujita, Yutaka Kawakami & Hiroyuki Hamakawa. (2013) Prognostic Impact of Expression of Bcl-2 and Bax Genes in Circulating Immune Cells Derived from Patients with Head and Neck Carcinoma. Neoplasia 15:3, pages 305-IN35.
Crossref
Crossref
Kevin P. Nikitczuk, Rene S. Schloss, Martin L. Yarmush & Edmund C. Lattime. (2013) PLGA-Polymer Encapsulating Tumor Antigen and CpG DNA Administered into the Tumor Microenvironment Elicits a Systemic Antigen-Specific IFN-γ Response and Enhances Survival. Journal of Cancer Therapy 04:01, pages 280-290.
Crossref
Crossref
Pamela L. Beatty & Olivera J. Finn. 2013. The Tumor Immunoenvironment. The Tumor Immunoenvironment
643
660
.
Theresa L. Whiteside. 2013. The Tumor Immunoenvironment. The Tumor Immunoenvironment
511
523
.
Anatoli Malyguine, Viktor Umansky & Michael R. Shurin. 2013. The Tumor Immunoenvironment. The Tumor Immunoenvironment
1
12
.
Erik H. J. G. Aarntzen, I. Jolanda M. de Vries, Joop H. Göertz, Marjo Beldhuis-Valkis, Huberdina M. L. M. Brouwers, Mandy W. M. M. van de Rakt, Renate G. van der Molen, Cornelis J. A. Punt, Gosse J. Adema, Paul J. Tacken, Irma Joosten & Joannes F. M. Jacobs. (2012) Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters. Cancer Immunology, Immunotherapy 61:11, pages 2003-2011.
Crossref
Crossref
Muzammal Hussain, Aqeel Javeed, Muhammad Ashraf, Nuha Al-Zaubai, Alastair Stewart & Muhammad Mahmood Mukhtar. (2012) Non-steroidal anti-inflammatory drugs, tumour immunity and immunotherapy. Pharmacological Research 66:1, pages 7-18.
Crossref
Crossref
C-J Shen, Z-H Yuan, Y-X Liu & G-Y Hu. (2012) Increased Numbers of T Helper 17 Cells and the Correlation with Clinicopathological Characteristics in Multiple Myeloma. Journal of International Medical Research 40:2, pages 556-564.
Crossref
Crossref
Marvin S. Melzer. (2012) Amino acid–anticodon binding specificity: rationale for a new class of therapeutic agent. Drug Discovery Today 17:7-8, pages 291-295.
Crossref
Crossref
Angelos D. Gritzapis, Ioannis F. Voutsas & Constantin N. Baxevanis. (2011) Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice. Cancer Immunology, Immunotherapy 61:3, pages 397-407.
Crossref
Crossref
Kazuaki Chikamatsu & Keisuke Masuyama. (2012) Recent Advances in Cancer Immunotherapy. Practica Oto-Rhino-Laryngologica 105:2, pages 87-94.
Crossref
Crossref
X-K Yuan, X-K Zhao, Y-C Xia, X Zhu & P Xiao. (2011)
Increased Circulating Immunosuppressive CD14
+
HLA-DR
−/Low
Cells Correlate with Clinical Cancer Stage and Pathological Grade in Patients with Bladder Carcinoma
. Journal of International Medical Research 39:4, pages 1381-1391.
Crossref
Crossref
Nathalie Labarriere, Amir Khammari, Francois Lang & Brigitte Dreno. (2011) Is antigen specificity the key to efficient adoptive T-cell therapy?. Immunotherapy 3:4, pages 495-505.
Crossref
Crossref
Adele Y. Wang, Sarah Q. Crome, Kristina M. Jenkins, Jeffrey A. Medin, Jonathan L. Bramson & Megan K. Levings. (2010) Adenoviral-transduced dendritic cells are susceptible to suppression by T regulatory cells and promote interleukin 17 production. Cancer Immunology, Immunotherapy 60:3, pages 381-388.
Crossref
Crossref
Theresa L. Whiteside, Magis Mandapathil, Miroslaw Szczepanski & Marta Szajnik. (2011) Mechanisms of tumor escape from the immune system: Adenosine-producing Treg, exosomes and tumor-associated TLRs. Bulletin du Cancer 98:2, pages E25-E31.
Crossref
Crossref